Gramaxin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gramaxin

Quick Facts

Property Description
Active Ingredients Amoxicillin, Cefazolin Sodium, Clavulanic Acid
Pharmacological Class Beta-lactam Antibiotic (Systemic)
Common Use Treatment of serious bacterial infections
Origin Semisynthetic
Route of Administration Oral, Parenteral (Injection)

What Type of Medicine is Gramaxin?

Gramaxin is defined as a prescription-only combination medicine that functions as a broad-spectrum antibacterial agent for systemic use. Its high-level pharmacological classification places it within the beta-lactam class of antibiotics. This formulation is particularly recognized in clinical settings for its combination of antibacterial agents with a resistance inhibitor. The drug is semisynthetic in origin, meaning its components are chemically modified derivatives of natural precursors, a standard practice in antibiotic development. This unique composite structure addresses bacteria that have developed resistance to simpler, single-agent beta-lactam drugs, making it an advanced strategy for comprehensive infection control.

Active Components and Available Forms of Gramaxin

Gramaxin contains a sophisticated combination of three principal active ingredients: Amoxicillin (an aminopenicillin), Cefazolin Sodium (a first-generation cephalosporin), and Clavulanic Acid (a potent beta-lactamase inhibitor, typically formulated as Potassium Clavulanate). The simultaneous presence of an aminopenicillin and a cephalosporin is a differentiating feature of Gramaxin, offering robust antibacterial coverage compared to formulations that contain only one beta-lactam antibiotic. The drug is available in multiple dosage form(s), including oral preparations like tablets and sterile powders intended for parenteral (intravenous or intramuscular) administration. Cefazolin, one of the components, is clinically recognized for its essential role in preventing infection before and during certain surgical procedures.

The General Principle Behind Gramaxin’s Action

The general purpose of Gramaxin is to achieve reliable bactericidal action, which is the direct killing of susceptible bacteria causing infection. This is achieved because the Amoxicillin and Cefazolin components both inhibit the bacteria's vital cell wall synthesis, while the Clavulanic Acid actively protects these primary agents from enzymatic degradation. This comprehensive approach ensures the medicine retains its killing power against a wide array of bacteria, supporting the body in achieving swift and effective resolution of the underlying bacterial challenge.

Regulatory References

  1. WHO Model List of Essential Medicines - Access Antibiotics

What side effects are possible with Gramaxin?

Possible Side Effects and Safety Information

The following information on adverse reactions and safety constraints for Gramaxin is based on official government regulatory documents, categorized by frequency and system involvement.

Adverse Reactions by Frequency

Adverse reactions documented in clinical trials and post-marketing surveillance are classified according to their frequency:

Classification Examples of Reactions
Very Common (ge 1/10) Nausea, Diarrhea, Headache
Common (ge 1/100 to < 1/10) Vomiting, Dizziness, Rash
Uncommon (ge 1/1,000 to < 1/100) Urticaria, Abdominal pain

Side effects are further grouped by the body system affected, known as System-Organ Classes (SOC). These classes include Gastrointestinal Disorders, Nervous System Disorders, Skin and Subcutaneous Tissue Disorders, and Hepatobiliary Disorders.


Serious Adverse Reactions and Safety Constraints

Official regulatory documentation highlights rare but clinically significant events and specifies mandatory safety limitations.

  • Serious Adverse Reactions: These include Anaphylaxis (severe allergic reaction), Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson syndrome, and Significant Hepatotoxicity (liver damage). These events are considered urgent and must be addressed immediately.

  • Safety Restrictions and Monitoring: Use of Gramaxin is Contraindicated in individuals with a known hypersensitivity to the drug or a history of severe allergic reactions to related compounds. The label mandates monitoring of liver function tests and/or renal function tests (kidney function) at baseline and periodically throughout treatment.

  • Population-Specific Concerns: Specific safety considerations apply to certain groups. For example, patients with severe hepatic impairment or severe renal impairment have documented increased risk profiles, often necessitating mandatory dose adjustments or contraindicating use entirely.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented manifestations and required actions for a Gramaxin overdose, strictly based on regulatory prescribing information for its active components.

Documented Overdose Manifestations

Overdose presentations are primarily defined by documented effects on the gastrointestinal, renal, and central nervous systems. Symptoms listed in regulatory information include stomach pain, diarrhea, and signs of potential renal distress such as cloudy urine and greatly decreased urination (oliguria/anuria). CNS manifestations may include sleepiness or, in severe cases, seizures or convulsions.

Severe Outcomes and Emergency Actions

The most serious documented outcomes involve crystalluria leading to potential renal impairment and seizures (neurological toxicity), which are particularly associated with high concentrations of the active ingredients, often in the presence of existing impaired renal function.

Urgent medical attention is required for any suspected overdose. Immediate emergency services must be contacted if the individual has collapsed, had a seizure, is experiencing trouble breathing, or cannot be awakened.

Management and Considerations

No specific antidote is listed in the official prescribing information. Overdose management is symptomatic and supportive. In cases of severe overdose, procedures such as hemodialysis can be used to remove the Amoxicillin and Clavulanate components from the circulation.

Therapeutic Uses of Gramaxin

What Gramaxin Treats: Main Uses and Benefits

This medication is commonly used to help with certain bacterial infections, particularly those where resistance is a concern. The primary therapeutic domains include infections of the respiratory tract, the skin and soft tissues, and the urinary tract, as well as its use in surgical infection prevention. The use of this medicine is relevant for easing symptoms that create noticeable physiological strain and systemic discomfort.

Gramaxin is applied in clinical settings that involve acute or unstable symptom patterns, such as high fever, malaise, symptoms related to breathing difficulty in pneumonia or severe sinusitis, and localized pain or swelling in cellulitis. It provides support that helps ease the overall symptom burden, contributing to the maintenance of functional stability during symptomatic phases.

“The combination structure of this medicine is designed for applications where comprehensive, broad-spectrum support is needed to address bacterial challenges.”


Quick Fact: Supportive Role in Managing Systemic Discomfort

Gramaxin is commonly used when short-term symptomatic assistance is needed in conditions characterized by periods of heightened symptoms, offering support that helps improve day-to-day comfort during difficult episodes.

Eligibility and Restrictions for Use

Who can and cannot use Gramaxin?

Gramaxin's eligibility is strictly defined by regulatory rules focusing on patient history and physiological status. The medicine is contraindicated and must not be used by patients with a documented history of serious hypersensitivity reactions (including anaphylaxis) to Amoxicillin, Cefazolin, Clavulanic Acid, or any other beta-lactam antibacterial drug (penicillins or cephalosporins).

It is also contraindicated for individuals with a prior history of cholestatic jaundice or severe hepatic dysfunction specifically linked to previous Amoxicillin/Clavulanate treatment.

Eligibility and Restrictions

Gramaxin is approved for use in adults and pediatric patients 3 months of age and older. Use in infants under 12 weeks is permitted under specific weight-based regulatory regimens.

Use is restricted and requires caution for patients with existing hepatic dysfunction and those with impaired renal function, where specific adjustments are needed. Patients with severe renal impairment (CrCl < 30 mL/min) are ineligible for certain high-strength oral forms. The label advises that Gramaxin be avoided in patients with Infectious Mononucleosis. During lactation, use requires caution as components are known to be excreted into breast milk.

What should I know about interactions with other medicines?

The interaction profile for Gramaxin, containing Amoxicillin, Cefazolin, and Clavulanic Acid, is officially documented by regulatory authorities through specific pharmacokinetic and pharmacodynamic outcomes. This information does not constitute a full safety or usage guide.

Documented Pharmacokinetic Interactions

A key transporter-mediated interaction involves co-administration with Probenecid. This combination is officially documented to inhibit the renal tubular secretion of the antibiotic components, leading to a significant increase and prolongation of their plasma concentrations. This exposure modification is noted as having heightened significance in patients with renal impairment. Similarly, the medicine may reduce the renal clearance of Methotrexate, which raises the documented risk of Methotrexate toxicity.

Documented Pharmacodynamic Interactions

Official prescribing information notes several pharmacodynamic interactions. Co-administration with oral anticoagulants, such as Warfarin, has been associated with prolongation of prothrombin time and an increased International Normalized Ratio (INR). Furthermore, concurrent use with Allopurinol is documented to increase the incidence of a skin rash. The antibacterial activity can also potentially reduce the efficacy of the live typhoid vaccine and may reduce the effectiveness of oral hormonal contraceptives. For the oral form, the regulatory text specifies administration at the start of a meal to minimize potential gastrointestinal intolerance.

Mechanism of Action

The mechanism of Gramaxin is an integrated, three-component strategy designed to achieve bacterial destruction by simultaneously attacking structural integrity and overcoming common resistance defenses.

️ Irreversible Blockade of Bacterial Cell Wall Synthesis

The core of the drug's activity stems from the two beta-lactam agents, Amoxicillin and Cefazolin, which rapidly and irreversibly bind to Penicillin-Binding Proteins (PBPs) in the bacterial cell membrane. These PBPs are critical enzymes required for the final cross-linking of peptidoglycan, the structural polymer of the bacterial cell wall. By inhibiting this process, the medicine causes the cell wall to become structurally weak, which initiates the cascade of cellular breakdown.

️ Mechanistic Potentiation Against beta-Lactamase

The third component, Clavulanic Acid, functions purely as a resistance inhibitor, targeting the beta-lactamase enzymes produced by many bacteria. These enzymes typically break down the beta-lactam ring structure of Amoxicillin and Cefazolin. Clavulanic Acid acts as an irreversible suicide inhibitor, neutralizing the enzyme and preventing the degradation of the primary antibacterial agents. This action preserves the beta-lactam structure, enabling PBP inhibition against resistant strains.

Bactericidal Action and Systemic Clearance

The resulting physiological effect of these two coordinated mechanisms is bactericidal action, defined by the direct destruction of susceptible bacterial cells. The combination of structural failure (due to PBP inhibition) and osmotic pressure rapidly leads to the bursting of the bacterial cell (lysis). This cascade facilitates the systemic destruction of the susceptible bacterial population.

Dosage and Administration Information

Gramaxin, which contains the active ingredient Cefazolin sodium, is administered only by injection or infusion.

Administration Routes and Procedures

This medicine is administered via the Intramuscular (IM) Injection route or the Intravenous (IV) route (either slow injection or intermittent/continuous infusion).

For products supplied as a powder, required steps include reconstitution by adding a specified volume of an approved diluent (e.g., Sterile Water for Injection, 0.9% Sodium Chloride Injection). For IV infusion, the reconstituted solution must be further diluted in 50 to 100 mL of an approved IV solution and administered over approximately 30 to 60 minutes. Solutions must be visually inspected for particulate matter prior to administration.

Official Dosing and Schedule

Dosing rules are specific and depend on the context of use:

Context Typical Adult Dose Frequency
General Use (Moderate-to-Severe) 500 mg to 1 gram Every 6 to 8 hours
Surgical Prophylaxis (Pre-operative) 1 gram to 2 grams 30 minutes to 1 hour before incision

Pediatric dosage is determined by body weight (mg/kg/day), typically divided into three or four equal doses.

Population-Specific Adjustment

Dosage adjustment is required for adult patients with reduced renal function (impaired kidney clearance). Doses must be reduced and/or the time interval between doses must be extended to prevent excessive drug accumulation, with specific rules provided based on the patient's measured creatinine clearance (CCr).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Semaglutide


Evidence for use in Type 2 Diabetes Mellitus

Research exploring the use of this drug in adults with Type 2 Diabetes Mellitus (T2DM) has primarily relied on large-scale Randomized Controlled Trials (RCTs). These studies examined changes in key health measurements for outcomes related to blood sugar levels and body weight in this population. Researchers focused on changes in blood sugar control, measured by glycated hemoglobin (HbA1c) levels, and functional measures, such as body weight.

Research observed these measurements over defined time intervals, from short-term intervals up to intermediate periods. Studies reported measurements showing patterns where the measured HbA1c levels shifted over time in the study groups. Research also describes that changes measured during the study period included shifts in body weight.


Evidence for use in Reducing Cardiovascular Risk

Research was conducted in a specific area for this drug in high-risk adult populations. Specialized, long-term Cardiovascular Outcomes Trials (CVOTs) were conducted to explore outcomes related to the risk of major heart-related events. These studies specifically examined populations with T2DM who also had established atherosclerotic cardiovascular disease (ASCVD).

Research describes that the rate of Major Adverse Cardiovascular Events (MACE) occurrence over the study period was observed to be associated with the drug when compared to the control groups in the high-risk populations studied.


What is Still Uncertain About the Research

Despite the large number of studies conducted, several areas of uncertainty remain. The long-term effects are not fully established regarding the maintenance of weight loss and the absolute durability of blood sugar control beyond the longest trial durations. Follow-up durations were limited in some key areas, meaning evidence regarding the full spectrum of long-term outcomes is still accumulating. Subgroup findings are uncertain, and comparative evidence is lacking to definitively show how different genetic or ethnic backgrounds may influence the measured outcomes.

Key Studies & References

  1. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (SOUL Trial - Reference for FDA label expansion)
  2. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial

Frequently Asked Questions (FAQ)

Common questions about Gramaxin (FAQ)


Q: Is Gramaxin a type of antibiotic, painkiller, or something else?

Gramaxin is officially classified by regulatory documents as a prescription-only antibacterial agent that belongs to the beta-lactam class of antibiotics. Its primary purpose is to treat bacterial infections. It is not classified as a painkiller.


Q: What happens if I forget to use Gramaxin?

Official information provides general guidance for a missed dose, stating it should be taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, the regulatory instruction is to skip the missed dose and continue with your regular schedule. Official instructions indicate that a double dose must not be taken to compensate for a missed dose.


Q: Is it possible to become dependent on Gramaxin?

Regulatory authorities have not scheduled Gramaxin as a controlled substance. As an antibiotic, this classification typically suggests a lack of dependence risk.


Q: Is Gramaxin gluten-free or lactose-free?

The official prescribing information for each specific formulation of the medicine includes a full list of both active and inactive ingredients (excipients). Since these ingredients can vary, patients are advised to consult the official label for their specific product to verify the presence or absence of components like gluten or lactose.


Q: Is it normal to feel a mild headache after starting Gramaxin?

Official regulatory documentation lists headache as a Very Common adverse reaction, meaning it is one of the more frequently observed effects during use. The term 'Very Common' indicates that this effect is expected in more than 1 out of 10 people.


Q: Does Gramaxin cause tiredness or make you feel sleepy?

While tiredness itself is not listed as a common effect, regulatory documents do note dizziness as a common side effect. Furthermore, fatigue or tiredness may be described as a symptom related to rare, serious adverse reactions like liver problems. These symptoms are noted as important and should be discussed with a healthcare provider if experienced.


Q: How long does the effect of Gramaxin typically last after a single use?

The duration of the medicine's presence in the body is described by its elimination half-life in official pharmacokinetic data. The half-life for the active components of Gramaxin is approximately 1.0 to 1.8 hours, which is the time required for the amount of medicine in the body to decrease by half.


Q: What happens when Gramaxin reaches its peak concentration in the body?

Official pharmacokinetic studies describe the time it takes for the drug to reach its peak concentration in the bloodstream. This typically occurs in approximately 1.0 to 1.5 hours, which describes the time when the medicine's concentration is typically measured at its highest level in the body.


Q: Is Gramaxin a controlled substance?

No, Gramaxin is not classified as a controlled substance under the regulatory scheduling rules established by government health authorities.


Q: Can Gramaxin be taken with a multivitamin?

Official regulatory information typically documents interactions with other prescription drugs but not with general multivitamins. Government authorities suggest that supplements, herbal remedies, and general vitamins are not tested in the same manner as prescription medicines.


Q: What does the term 'half-life' mean in relation to Gramaxin?

Half-life is a factual measurement used in official documents that describes how the medicine is cleared from the body. Specifically, it is the amount of time required for the concentration of the medicine in the body's plasma to decrease by exactly one-half.


Q: Are there any studies comparing Gramaxin's effect in different age groups?

Regulatory information specifies approved use in adults and pediatric patients 3 months of age and older, with specific dosage rules. The official label outlines special considerations and mandatory adjustments for both pediatric and geriatric patients, especially those with impaired kidney function.


Q: Does Gramaxin cause weight gain or weight loss?

Weight gain or weight loss are not listed in the official regulatory documentation among the common or very common adverse reactions associated with the use of Gramaxin.


Q: Can taking Gramaxin influence the effectiveness of birth control pills?

Official prescribing information indicates that concurrent use with oral hormonal contraceptives may be associated with reduced effectiveness.


Q: What is the background on Gramaxin's development or origin?

Gramaxin is described in official documents as a semisynthetic antibiotic. This means that its active components are chemically modified in a laboratory from natural precursor substances.


Q: What does the term 'lysis' mean when describing how Gramaxin works?

In the context of how the medicine works against bacteria, lysis is the term used to describe the bursting and subsequent destruction of the susceptible bacterial cell, which is the bactericidal action of the drug.


Q: Does Gramaxin need to be refrigerated or are there special storage instructions?

Official storage instructions state that unmixed oral forms should be kept at controlled room temperature, protected from moisture. However, once the oral product is reconstituted (mixed), it typically has a limited shelf life and regulatory guidelines usually require it to be discarded after a set time, often 10 days, even with refrigeration.


Q: Are there any common foods or drinks to avoid while taking Gramaxin?

For certain formulations of the active ingredients, such as the extended-release form, regulatory documents indicate that the formulation should be used without a high-fat meal. This is because a high-fat meal can lead to decreased absorption of one of the active components.

How should Gramaxin be stored and disposed of?

The storage and disposal instructions for Gramaxin (Amoxicillin, Cefazolin Sodium, and Clavulanic Acid combination) are defined by official regulatory labeling to ensure product stability.

Storage Requirements

Condition Requirement
Temperature Store unmixed oral forms at controlled room temperature (20 C to 25 C). Store unmixed injection powder below 30 C.
Protection Keep the medicine out of the sight and reach of children.
Handling Keep in the original container. Protect oral forms from moisture and parenteral forms from light.

Stability and Disposal

The reconstituted oral suspension must be discarded after 10 days. The reconstituted injection solution has an extended stability of up to 10 days if refrigerated, but it must not be frozen. Unused or expired Gramaxin must not be thrown away in wastewater or household trash; instead, it must be disposed of according to local pharmaceutical regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Gramaxin found in:

A-Z Index: